Thermo Fisher Scientific is investing more than $475 million in new capabilities and capacity in 2020 around three areas of greatest demand: biologics, cell and gene therapy, and drug product development and commercial capabilities. This investment, in addition to those made in 2019, brings the total investment over two years to approximately $800 million across the company’s pharma services business. Thermo Fisher’s St. Louis site completed its $50 million expansion, doubling ...